{"entity":{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","aka":[],"tldr":"Lead-212 alpha-therapy company whose SSTR2 agent [212Pb]VMT-α-NET reported a 43% response rate in neuroendocrine tumours and is heading for phase 3.","summary":"Phase 1/2a of [212Pb]VMT-α-NET (NCT05636618): 43% ORR in cohort 2 with 72% progression-free/alive at the 2026 update; 76 NET patients treated by July 2026; first meningioma patient dosed June 2026; EU orphan designation July 2026. Phase 3 planned at a cumulative 20 mCi dose. Also developing PSMA and melanocortin-1 receptor 212Pb agents.","asOf":"2026-09-04","links":[{"label":"Q2 2026 highlights","url":"https://www.globenewswire.com/news-release/2026/08/10/3342260/0/en/perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2026-results.html"}],"tags":[],"related":[],"cancers":["neuroendocrine"],"sections":["radiopharma"],"technologies":["targeted-alpha-therapy"],"targets":["sstr2","psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["alpha-vs-beta"],"trials":["nct05655312","nct05636618","nct06710756"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seattle, WA","country":"US","companyType":"radiopharma","website":"https://perspectivetherapeutics.com","ticker":"CATX","investors":[],"funding":[]},"route":"/companies/perspective-therapeutics/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"alpha-nanogenerators","kind":"technology","name":"Alpha-emitter nanogenerators and daughter trapping","route":"/technologies/alpha-nanogenerators/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"term":[{"id":"alpha-vs-beta","kind":"term","name":"Alpha vs beta emitters","route":"/terms/alpha-vs-beta/"}],"trial":[{"id":"nct06710756","kind":"trial","name":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","route":"/trials/nct06710756/"},{"id":"nct05655312","kind":"trial","name":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","route":"/trials/nct05655312/"},{"id":"nct05636618","kind":"trial","name":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","route":"/trials/nct05636618/"}],"idea":[{"id":"idea-reg-alpha-emitter-portfolio","kind":"idea","name":"Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211","route":"/ideas/idea-reg-alpha-emitter-portfolio/"}]}}